BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company research and development of innovative biological drugs, such as antibodies, that address high unmet medical needs. Its therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, the company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, it develops lecanemab phase 3 clinical trial, Lecanemab back-up phase 3 clinical trial, BAN1503 is in discovery stage, and Exidavnemab is in phase 2 clinical trial, Lecanemab is in preclinical; and BAN2803, BAN2802 preclinical trial; PD-BT2238, ND-BT3814, and GD-BT6822 in discovery stage. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.